AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33040383 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection therapy
Number of subjects: 286
Study 33040420 — intervention group
Group type: EXPERIMENTAL
Intervention: UCSF downstaging (UCSF-DS)
Number of subjects: 2002
Study 33040420 — intervention group
Group type: EXPERIMENTAL
Intervention: All-comers policy
Number of subjects: 2002
Study 33040420 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP score ≤2 points
Number of subjects: 2002
Study 33040420 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Eligibility Criteria (DEC)
Number of subjects: 2002
Study 33040580 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative flow ratio (QFR) based functional SYNTAX score (FSS)
Number of subjects: 607
Study 33040580 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 607
Study 33040720 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 23
Study 33040720 — intervention group
Group type: EXPERIMENTAL
Intervention: cAMP Pathway Protein Retention
Number of subjects: 23
Study 33041107 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm of Urban Training (NCT01897298)
Number of subjects: 291
Study 33041107 — intervention group
Group type: COMPARATOR
Intervention: PROactive initial validation (NCT01388218)
Number of subjects: 291
Study 33041337 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall alcohol consumption (drinks/week)
Number of subjects: 226162
Study 33041337 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking pattern (1-3 days/week vs 4-7 days)
Number of subjects: 226162
Study 33041987 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic Organization Strategy Training (SOST)
Number of subjects: 0
Study 33041987 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation Intervention (PI)
Number of subjects: 0
Study 33042202 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and aromatase inhibitor therapy (AIT)
Number of subjects: 142
Study 33042366 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative dance classes (12-week duration)
Number of subjects: 7
Study 33042568 — intervention group
Group type: EXPERIMENTAL
Intervention: SINEX program (12-week exercise program with physiotherapist-supervised sessions)
Number of subjects: 7
Study 33042568 — intervention group
Group type: EXPERIMENTAL
Intervention: SINEX program
Number of subjects: 7
Study 33042569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored lifestyle intervention delivered by peer coaches via 3 core home visits every 4-6 weeks and additional support via text.
Number of subjects: 100
Study 33042569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored lifestyle intervention delivered by peer coaches.
Number of subjects: 100
Study 33042571 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week Goal Management Training (GMT) program
Number of subjects: 19
Study 33042571 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 19
Study 33042571 — intervention group
Group type: COMPARATOR
Intervention: Both groups (active and control)
Number of subjects: 19
Study 33042579 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusions of 4 mg/kg tocilizumab (TCZ)
Number of subjects: 37
Study 33042579 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusions of 8 mg/kg tocilizumab (TCZ)
Number of subjects: 37
Study 33042579 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no treatment)
Number of subjects: 37
Study 33042916 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/Detergent-Treated Plasma
Number of subjects: 0
Study 33042935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce excessive drinking, details not available
Number of subjects: 0
Study 33042935 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33043164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, up to 800 mg, single shot)
Number of subjects: 0
Study 33043304 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 4 cycles of BEP chemotherapy (high-intensity cisplatin)
Number of subjects: 53
Study 33043304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial bradykinin, acetylcholine, and sodium nitroprusside
Number of subjects: 53
Study 33043735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tosedostat
Number of subjects: 0
Study 33044119 — intervention group
Group type: EXPERIMENTAL
Intervention: Viabahn endoprosthesis with Propaten bioactive surface
Number of subjects: 0
Study 33044494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 3074
Study 33044494 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment group
Number of subjects: 3074
Study 33044494 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 3074
Study 33044566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensartinib (200 mg/100 μCi)
Number of subjects: 6
Study 33044747 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 38160
Study 33045006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionized calcium level
Number of subjects: 883
Study 33045006 — intervention group
Group type: COMPARATOR
Intervention: Calcium level
Number of subjects: 883
Study 33045104 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 478
Study 33045316 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wP) at 80 mg/m² for 6 weeks + Low-dose fractionated whole abdominal radiation therapy (LDFWART)
Number of subjects: 10
Study 33045380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 0
Study 33045409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-stage-2 SVHD infants
Number of subjects: 29
Study 33045409 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study 33045496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600-mg Dose 2 or 3 infused over approximately 2 hours (Cohort 1)
Number of subjects: 141
Study 33045496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 300-mg Dose 1, Infusion 2 over approximately 1.5 hours (Cohort 2)
Number of subjects: 141
Study 33045496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (both cohorts)
Number of subjects: 141
Study 33045664 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal therapy (LITT)
Number of subjects: 60
Study 33045668 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥4 lifestyle risk factors
Number of subjects: 535
Study 33045668 — intervention group
Group type: COMPARATOR
Intervention: Zero or one risk factor
Number of subjects: 535
Study 33045668 — intervention group
Group type: COMPARATOR
Intervention: Two risk factors
Number of subjects: 535
Study 33045668 — intervention group
Group type: COMPARATOR
Intervention: Three risk factors
Number of subjects: 535
Study 33045668 — intervention group
Group type: COMPARATOR
Intervention: Four risk factors
Number of subjects: 535
Study 33045668 — intervention group
Group type: COMPARATOR
Intervention: ≥5 risk factors
Number of subjects: 535
Study 33045668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle habits (six factors)
Number of subjects: 535
Study 33045668 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depression
Number of subjects: 535
Study 33045994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts from low/high to middle category (L-M/H-M) for phosphorus
Number of subjects: 0
Study 33045994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts from middle to low/high category (M-L/M-H) for phosphorus
Number of subjects: 0
Study 33045994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts from low/middle to high category (L-H/M-H) for calcium
Number of subjects: 0
Study 33045994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts from high to middle category (H-M) for calcium
Number of subjects: 0
Study 33045994 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts from low to middle category (L-M) for intact parathyroid hormone
Number of subjects: 0
Study 33045994 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in 3-month patterns of phosphorus and calcium toward the middle category
Number of subjects: 0
Study 33045994 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding hypercalcemia
Number of subjects: 0
Study 33046003 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintended pregnancies
Number of subjects: 870
Study 33046066 — intervention group
Group type: EXPERIMENTAL
Intervention: ART with frequent viral load testing until achieving undetectable viral load (ART-VL)
Number of subjects: 0
Study 33046066 — intervention group
Group type: EXPERIMENTAL
Intervention: daily oral pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study 33046066 — intervention group
Group type: EXPERIMENTAL
Intervention: semen-washing with intrauterine insemination
Number of subjects: 0
Study 33046066 — intervention group
Group type: EXPERIMENTAL
Intervention: manual self-insemination at home
Number of subjects: 0
Study 33046066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ART-VL plus PrEP
Number of subjects: 0
Study 33046066 — intervention group
Group type: COMPARATOR
Intervention: Current HIV clinical practices
Number of subjects: 0
Study 33046203 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes mellitus (DM)
Number of subjects: 235
Study 33046203 — intervention group
Group type: COMPARATOR
Intervention: Patients without diabetes mellitus (DM)
Number of subjects: 235
Study 33046437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioband tricuspid valve reconstruction system
Number of subjects: 30
Study 33046513 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intratumoral injection
Number of subjects: 24
Study 33046516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus osimertinib
Number of subjects: 25
Study 33046518 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226) administered intravenously at a dosage of 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Number of subjects: 37
Study 33046518 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab (GB226)
Number of subjects: 37
Study 33046517 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90011 at 60 mg once per week (RP2D)
Number of subjects: 50
Study 33046517 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90011 at 120 mg once per week (NTD)
Number of subjects: 50
Study 33046517 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90011 at 80 mg once per week (MTD)
Number of subjects: 50
Study 33046517 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90011
Number of subjects: 50
Study 33046573 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-integrated risk profile-based recommendations for either observation, vaginal brachytherapy or external pelvic beam radiotherapy
Number of subjects: 500
Study 33046573 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant vaginal brachytherapy
Number of subjects: 500
Study 33046621 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 820 (1100 mg or 1400 mg) plus pembrolizumab (200 mg) intravenously every 3 weeks
Number of subjects: 116
Study 33046765 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medications with a reduction in hsCRP levels of 40% or greater (responder group)
Number of subjects: 0
Study 33046765 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medications with a reduction in hsCRP levels of less than 40% (non-responder group)
Number of subjects: 0
Study 33046861 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven computational model of similarity judgements for real-world images of objects
Number of subjects: 1854
Study 33046861 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven computational model
Number of subjects: 1854
Study 33046861 — intervention group
Group type: EXPERIMENTAL
Intervention: Human similarity judgements
Number of subjects: 1854
Study 33046868 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous NKT cells engineered to co-express a GD2-specific chimeric antigen receptor (CAR) with interleukin-15
Number of subjects: 3
Study 33046870 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunotherapy with anti-PD1 plus anti-CTLA4 antibodies
Number of subjects: 0
Study 33046998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparin, dosage based on weight, D-dimer levels, and clinical condition.
Number of subjects: 80
Study 33047248 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraOmmaya antiGD2 monoclonal antibody
Number of subjects: 61
Study 33047298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant topical corticosteroids
Number of subjects: 740
Study 33047329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 928
Study 33047329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose adjustments to 40 mg/day for IM patients and 80 mg/day for PM patients
Number of subjects: 928
Study 33047329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose increase to 60 mg/day for PM patients
Number of subjects: 928
Study 33047430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 113
Study 33047438 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 33047438 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 0
Study 33047583 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil CD64 index (iCD64n) measured on postoperative days 3 and 6
Number of subjects: 73
Study 33047816 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume evacuator (HVE)
Number of subjects: 425
Study 33047816 — intervention group
Group type: COMPARATOR
Intervention: High-volume evacuator (HVE) vs. conventional dental suction
Number of subjects: 425
Study 33047816 — intervention group
Group type: COMPARATOR
Intervention: Dental isolation combination system (Isolite)
Number of subjects: 425
Study 33047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam
Number of subjects: 425
Study 33047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam plus HVE
Number of subjects: 425
Study 33047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Local stand-alone air cleaning system (ACS)
Number of subjects: 425
Study 33047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminar flow with HEPA filter
Number of subjects: 425
Study 33047816 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial coolants (chlorhexidine, povidone iodine, cinnamon extract)
Number of subjects: 425
Study 33047816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine coolant
Number of subjects: 425
Study 33048057 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote titration facilitated by telemonitoring using a smartphone-based system
Number of subjects: 76
Study 33048057 — intervention group
Group type: COMPARATOR
Intervention: Standard titration program consisting of in-office visits
Number of subjects: 76
Study 33048203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab (loading dose on Day 1, maintenance doses every 4-8 weeks)
Number of subjects: 10
Study 33048203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 10
Study 33048619 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy antitumor activity in underexplored cancer types (specific treatments not detailed)
Number of subjects: 5954
Study 33048900 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented renal clearance predictor
Number of subjects: 10259
Study 33048900 — intervention group
Group type: COMPARATOR
Intervention: Existing models for augmented renal clearance
Number of subjects: 10259
Study 33049057 — intervention group
Group type: EXPERIMENTAL
Intervention: TN-depleted peripheral blood stem cell (PBSC) grafts
Number of subjects: 0
Study 33049057 — intervention group
Group type: COMPARATOR
Intervention: Standard unselected HCT
Number of subjects: 0
Study 33049248 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33049644 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-11 PGD criteria
Number of subjects: 539
Study 33049644 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded supplementary questionnaire of culturally-bound grief symptoms
Number of subjects: 539
Study 33049644 — intervention group
Group type: COMPARATOR
Intervention: Standard PGD network
Number of subjects: 539
Study 33050261 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 33050459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangafodipir or other SOD mimetics
Number of subjects: 0
Study 33050459 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33050804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) - sunitinib, pazopanib, sorafenib
Number of subjects: 151
Study 33050890 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA)
Number of subjects: 221
Study 33050890 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 221
Study 33050890 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with JIA using synthetic and biologic DMARDs
Number of subjects: 221
Study 33051036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) for 6 months
Number of subjects: 101
Study 33051234 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly community dance sessions designed for people with breathlessness, lasting 75 min, led by a trained community dance leader.
Number of subjects: 8
Study 33051264 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab plus standard therapy
Number of subjects: 362
Study 33051264 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 362
Study 33051459 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term leptin administration
Number of subjects: 0
Study 33051459 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term leptin treatment
Number of subjects: 0
Study 33051459 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 0
Study 33051668 — intervention group
Group type: EXPERIMENTAL
Intervention: Darinaparsin 200 mg/m2/day in 4-week cycles
Number of subjects: 23
Study 33051668 — intervention group
Group type: EXPERIMENTAL
Intervention: Darinaparsin 300 mg/m2/day in 4-week cycles
Number of subjects: 23
Study 33051668 — intervention group
Group type: EXPERIMENTAL
Intervention: Darinaparsin 300 mg/m2/day in 3-week cycles
Number of subjects: 23
Study 33051855 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal museum of fine arts (MMFA) participatory art-based activities, one weekly structured workshop over a 3-month period.
Number of subjects: 101
Study 33052476 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized swallowing test performed 24 hours after extubation
Number of subjects: 138
Study 33052476 — intervention group
Group type: EXPERIMENTAL
Intervention: Second swallowing test performed 48 hours after the first test
Number of subjects: 138
Study 33052476 — intervention group
Group type: COMPARATOR
Intervention: Comparison of characteristics between patients with persistent SD and those without or with transient SD
Number of subjects: 138
Study 33052476 — intervention group
Group type: COMPARATOR
Intervention: Duration of ICU stay after first extubation
Number of subjects: 138
Study 33052476 — intervention group
Group type: COMPARATOR
Intervention: Delay to oral feeding
Number of subjects: 138
Study 33052556 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg plus gefitinib 250 mg orally once daily
Number of subjects: 64
Study 33052718 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33052753 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33053154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in PX patients
Number of subjects: 10
Study 33053284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2007
Study 33053284 — intervention group
Group type: COMPARATOR
Intervention: Usual obesity care (control group)
Number of subjects: 2007
Study 33053612 — intervention group
Group type: COMPARATOR
Intervention: Oil-soluble contrast media (OSCM)
Number of subjects: 3864
Study 33053612 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble contrast media (WSCM)
Number of subjects: 3864
Study 33054054 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2 alterations
Number of subjects: 499
Study 33054054 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL2 gene and protein expression levels
Number of subjects: 499
Study 33054054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutational subsets
Number of subjects: 499
Study 33054084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab-CHL (O-CHL)
Number of subjects: 383
Study 33054084 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (CHL)
Number of subjects: 383
Study 33054114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric-inspired chemotherapy incorporating 6 doses of pegaspargase 2000 IU/m2
Number of subjects: 39
Study 33054130 — intervention group
Group type: COMPARATOR
Intervention: CC variant
Number of subjects: 79
Study 33054130 — intervention group
Group type: EXPERIMENTAL
Intervention: TT variant
Number of subjects: 79
Study 33054130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both variants
Number of subjects: 79
Study 33054753 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Move app-based intervention (parent-child exercises)
Number of subjects: 67
Study 33054845 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention combining clinical obesity preceptorship and electronic networking tools
Number of subjects: 35
Study 33054971 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33055233 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic foot ulcer prevention program with once-daily foot temperature monitoring
Number of subjects: 80
Study 33055274 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 1866
Study 33055274 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirin group
Number of subjects: 1866